[Form 4] Hoth Therapeutics, Inc. Insider Trading Activity
Robb Knie, CEO and President and a director of Hoth Therapeutics, acquired 800,000 shares of restricted common stock under the company鈥檚 Amended and Restated 2022 Equity Incentive Plan; the award vested in full at grant and was issued at $0 per share, bringing his post-award beneficial ownership to 858,131 shares. The next day he sold 310,744 shares at $1.21 per share, reducing his beneficial ownership to 547,387 shares. The Form 4 shows the acquisition was labeled as an issuance that vested on grant and the sale was reported separately. The filing was signed by an attorney-in-fact on behalf of Mr. Knie.
Robb Knie, amministratore delegato, presidente e membro del consiglio di Hoth Therapeutics, ha acquisito 800.000 azioni vincolate ordinarie ai sensi dell鈥橝mended and Restated 2022 Equity Incentive Plan della societ脿; il premio 猫 maturato completamente alla data di concessione ed 猫 stato emesso a $0 per azione, portando la sua partecipazione beneficiaria post-concessione a 858.131 azioni. Il giorno successivo ha venduto 310.744 azioni a $1,21 per azione, riducendo la sua partecipazione beneficiaria a 547.387 azioni. Il modulo Form 4 indica che l鈥檃cquisizione 猫 stata registrata come un鈥檈missione con maturazione alla data di concessione e che la vendita 猫 stata riportata separatamente. Il documento 猫 stato firmato da un mandatario legale per conto del sig. Knie.
Robb Knie, consejero delegado, presidente y director de Hoth Therapeutics, adquiri贸 800.000 acciones ordinarias restringidas en virtud del Amended and Restated 2022 Equity Incentive Plan de la compa帽铆a; el premio se hizo efectivo por completo en la concesi贸n y se emiti贸 a $0 por acci贸n, elevando su participaci贸n beneficiaria tras la adjudicaci贸n a 858.131 acciones. Al d铆a siguiente vendi贸 310.744 acciones a $1,21 por acci贸n, reduciendo su participaci贸n beneficiaria a 547.387 acciones. El Formulario 4 muestra que la adquisici贸n se registr贸 como una emisi贸n que venci贸 al momento de la concesi贸n y que la venta se inform贸 por separado. La presentaci贸n fue firmada por un apoderado en nombre del Sr. Knie.
Robb Knie電� Hoth Therapeutics鞚� CEO鞚挫瀽 靷灔 瓴� 鞚挫偓搿滌劀 須岇偓鞚� Amended and Restated 2022 Equity Incentive Plan鞐� 霐半澕 800,000欤检潣 鞝滍暅 氤错喌欤茧ゼ 旆摑頄堨姷雼堧嫟. 頃措嫻 氤挫儊鞚� 攵�鞐� 鞁� 鞝勳暋 甓岆Μ頇曥爼(vested)霅橃棃瓿� 欤茧嫻 $0搿� 氚滍枆霅橃柎 攵�鞐� 頉� 攴胳潣 鞁れ鞝� 氤挫湢 欤检嫕 靾橂姅 858,131欤�臧� 霅橃棃鞀惦媹雼�. 雼れ潓 雮� 攴鸽姅 310,744欤�毳� 欤茧嫻 $1.21鞐� 毵り皝頃� 鞁れ鞝� 氤挫湢 欤检嫕 靾橁皜 547,387欤�搿� 欷勳柎霌れ棃鞀惦媹雼�. Form 4鞐愲姅 頃措嫻 旆摑鞚� 攵�鞐� 鞁滌爯鞐� 甓岆Μ頇曥爼霅� 氚滍枆鞙茧 響滉赴霅橃柎 鞛堦碃 毵り皝鞚� 氤勲弰搿� 氤搓碃霅橃棃雼り碃 旮办灛霅橃柎 鞛堨姷雼堧嫟. 頃措嫻 靹滊電� Knie 鞌ゼ 雽�毽暅 氩曤 雽�毽澑鞚� 靹滊獏頄堨姷雼堧嫟.
Robb Knie, PDG, pr茅sident et administrateur de Hoth Therapeutics, a acquis 800 000 actions ordinaires restreintes dans le cadre de l鈥橝mended and Restated 2022 Equity Incentive Plan de la soci茅t茅聽; l鈥檃ttribution a 茅t茅 int茅gralement acquise 脿 la date d鈥檕ctroi et a 茅t茅 茅mise 脿 0 $ par action, portant sa d茅tention b茅n茅ficiaire apr猫s attribution 脿 858 131 actions. Le lendemain, il a vendu 310 744 actions 脿 1,21 $ par action, r茅duisant sa d茅tention b茅n茅ficiaire 脿 547 387 actions. Le formulaire Form 4 indique que l鈥檃cquisition a 茅t茅 libell茅e comme une 茅mission acquise 脿 l鈥檕ctroi et que la vente a 茅t茅 d茅clar茅e s茅par茅ment. Le dossier a 茅t茅 sign茅 par un mandataire au nom de M. Knie.
Robb Knie, CEO, Pr盲sident und Direktor von Hoth Therapeutics, erwarb 800.000 eingeschr盲nkte Stammaktien im Rahmen des Amended and Restated 2022 Equity Incentive Plan des Unternehmens; die Zuwendung war zum Zeitpunkt der Gew盲hrung vollst盲ndig unverfallbar und wurde zu $0 pro Aktie ausgegeben, wodurch sein wirtschaftliches Eigentum nach der Zuwendung 858.131 Aktien betrug. Am folgenden Tag verkaufte er 310.744 Aktien zu $1,21 pro Aktie, womit sein wirtschaftliches Eigentum auf 547.387 Aktien sank. Im Form 4 ist die Erwerbung als Ausgabe, die bei Gew盲hrung unverfallbar war, angegeben und der Verkauf separat gemeldet. Die Einreichung wurde von einem Bevollm盲chtigten im Namen von Herrn Knie unterzeichnet.
- Transparency: Transactions were disclosed on Form 4, meeting SEC reporting requirements
- Compensation alignment: Large restricted stock grant under the company's equity plan ties CEO compensation to equity value
- Reduced insider stake: Sale of 310,744 shares lowered the CEO's direct beneficial ownership from 858,131 to 547,387 shares
- Immediate vesting: The restricted stock vested in full upon grant, removing future service-based retention conditions
Insights
TL;DR: Issuance of vested restricted stock aligns executive incentives, followed by a partial sale reducing insider stake.
The report documents an immediate vesting grant of 800,000 restricted shares to the CEO under the 2022 Equity Incentive Plan and a subsequent disposition of 310,744 shares at $1.21 each. Immediate vesting removes future service-based retention conditions, which can dilute incentives tied to continued performance. The partial sale reduces the CEO鈥檚 direct holding to 547,387 shares, which is material to governance discussions because insider ownership levels affect alignment with shareholders. The disclosure appears complete for the reported transactions.
TL;DR: Material insider activity: large zero-cost grant followed by a meaningful sale at $1.21 reduces reported holdings.
The Form 4 shows a net change from 858,131 to 547,387 shares after the two reported transactions. The grant was issued at $0, indicating compensation rather than a market purchase. The sale of 310,744 shares at $1.21 generated realized proceeds (not stated on the form) and meaningfully lowered direct beneficial ownership on record. For investors, these are clear changes in insider exposure; the transactions are routine to report and no derivative securities were reported.
Robb Knie, amministratore delegato, presidente e membro del consiglio di Hoth Therapeutics, ha acquisito 800.000 azioni vincolate ordinarie ai sensi dell鈥橝mended and Restated 2022 Equity Incentive Plan della societ脿; il premio 猫 maturato completamente alla data di concessione ed 猫 stato emesso a $0 per azione, portando la sua partecipazione beneficiaria post-concessione a 858.131 azioni. Il giorno successivo ha venduto 310.744 azioni a $1,21 per azione, riducendo la sua partecipazione beneficiaria a 547.387 azioni. Il modulo Form 4 indica che l鈥檃cquisizione 猫 stata registrata come un鈥檈missione con maturazione alla data di concessione e che la vendita 猫 stata riportata separatamente. Il documento 猫 stato firmato da un mandatario legale per conto del sig. Knie.
Robb Knie, consejero delegado, presidente y director de Hoth Therapeutics, adquiri贸 800.000 acciones ordinarias restringidas en virtud del Amended and Restated 2022 Equity Incentive Plan de la compa帽铆a; el premio se hizo efectivo por completo en la concesi贸n y se emiti贸 a $0 por acci贸n, elevando su participaci贸n beneficiaria tras la adjudicaci贸n a 858.131 acciones. Al d铆a siguiente vendi贸 310.744 acciones a $1,21 por acci贸n, reduciendo su participaci贸n beneficiaria a 547.387 acciones. El Formulario 4 muestra que la adquisici贸n se registr贸 como una emisi贸n que venci贸 al momento de la concesi贸n y que la venta se inform贸 por separado. La presentaci贸n fue firmada por un apoderado en nombre del Sr. Knie.
Robb Knie電� Hoth Therapeutics鞚� CEO鞚挫瀽 靷灔 瓴� 鞚挫偓搿滌劀 須岇偓鞚� Amended and Restated 2022 Equity Incentive Plan鞐� 霐半澕 800,000欤检潣 鞝滍暅 氤错喌欤茧ゼ 旆摑頄堨姷雼堧嫟. 頃措嫻 氤挫儊鞚� 攵�鞐� 鞁� 鞝勳暋 甓岆Μ頇曥爼(vested)霅橃棃瓿� 欤茧嫻 $0搿� 氚滍枆霅橃柎 攵�鞐� 頉� 攴胳潣 鞁れ鞝� 氤挫湢 欤检嫕 靾橂姅 858,131欤�臧� 霅橃棃鞀惦媹雼�. 雼れ潓 雮� 攴鸽姅 310,744欤�毳� 欤茧嫻 $1.21鞐� 毵り皝頃� 鞁れ鞝� 氤挫湢 欤检嫕 靾橁皜 547,387欤�搿� 欷勳柎霌れ棃鞀惦媹雼�. Form 4鞐愲姅 頃措嫻 旆摑鞚� 攵�鞐� 鞁滌爯鞐� 甓岆Μ頇曥爼霅� 氚滍枆鞙茧 響滉赴霅橃柎 鞛堦碃 毵り皝鞚� 氤勲弰搿� 氤搓碃霅橃棃雼り碃 旮办灛霅橃柎 鞛堨姷雼堧嫟. 頃措嫻 靹滊電� Knie 鞌ゼ 雽�毽暅 氩曤 雽�毽澑鞚� 靹滊獏頄堨姷雼堧嫟.
Robb Knie, PDG, pr茅sident et administrateur de Hoth Therapeutics, a acquis 800 000 actions ordinaires restreintes dans le cadre de l鈥橝mended and Restated 2022 Equity Incentive Plan de la soci茅t茅聽; l鈥檃ttribution a 茅t茅 int茅gralement acquise 脿 la date d鈥檕ctroi et a 茅t茅 茅mise 脿 0 $ par action, portant sa d茅tention b茅n茅ficiaire apr猫s attribution 脿 858 131 actions. Le lendemain, il a vendu 310 744 actions 脿 1,21 $ par action, r茅duisant sa d茅tention b茅n茅ficiaire 脿 547 387 actions. Le formulaire Form 4 indique que l鈥檃cquisition a 茅t茅 libell茅e comme une 茅mission acquise 脿 l鈥檕ctroi et que la vente a 茅t茅 d茅clar茅e s茅par茅ment. Le dossier a 茅t茅 sign茅 par un mandataire au nom de M. Knie.
Robb Knie, CEO, Pr盲sident und Direktor von Hoth Therapeutics, erwarb 800.000 eingeschr盲nkte Stammaktien im Rahmen des Amended and Restated 2022 Equity Incentive Plan des Unternehmens; die Zuwendung war zum Zeitpunkt der Gew盲hrung vollst盲ndig unverfallbar und wurde zu $0 pro Aktie ausgegeben, wodurch sein wirtschaftliches Eigentum nach der Zuwendung 858.131 Aktien betrug. Am folgenden Tag verkaufte er 310.744 Aktien zu $1,21 pro Aktie, womit sein wirtschaftliches Eigentum auf 547.387 Aktien sank. Im Form 4 ist die Erwerbung als Ausgabe, die bei Gew盲hrung unverfallbar war, angegeben und der Verkauf separat gemeldet. Die Einreichung wurde von einem Bevollm盲chtigten im Namen von Herrn Knie unterzeichnet.
FAQ
What changes in ownership did Robb Knie report on the Form 4 for HOTH?
Were any derivative securities reported by the insider on this Form 4 for Hoth Therapeutics (HOTH)?
Under what plan were the 800,000 restricted shares issued to the CEO?
At what price were the restricted shares issued and the sold shares transacted?
Who signed the Form 4 filing on behalf of Robb Knie?
